Study population
Diagnostic TestDyspnea assessment (NYHA functional class) EKG Echocardiography
NCT Number: NCT03719027
The prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) varies widely (0.4% to 8.8%) in the literature. This large variation could be due to the inclusion of patients with pre-existing CTEPH revealed on the occasion of a recurrence of PE. However, the absence of hemodynamic data when diagnosing PE does not allow to distinguish these patients. A prospective multicentric study involving 146 patients showed that the majority of patients with CTEPH during follow-up had a pulmonary hypertension unknown at the time of PE diagnosis. It is necessary to confirm these results in a broader study.
The aim of this study is to evaluate the cumulative incidence of CTEPH after a PE.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
CHU Jean Minjoz, Besançon, France
The patients selected in this study are patients with an objectively confirmed PE and previously included since at least 12 months in one of the studies of the INNOVTE network.
Patients who are alive at the time of the selection for the PREVA-CTEPH study are contacted by phone or by mail for inclusion in the prospective interventional part of the PREVA-CTEPH study. Patients who consent to participate to this prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH. Patients with dyspnea (NYHA >1) and/or a high or intermediate echocardiographic probability of pulmonary hypertension (ESC criteria) have a V/Q lung scan, a right heart catheterization and a pulmonary angiography to objectively confirm the diagnosis of CTEPH according to the current ESC guidelines.
Retrospective phase: All clinical (dyspnea, signs of right ventricular insufficiency...), echocardiographic and imaging (pulmonary angiography, V/Q lung scan) relevant data after the diagnosis of index PE are retrieved from the clinical chart of each patients alive at the time of the selection for the PREVA-CTEPH study and/or with a diagnosis of CTEPH confirmed after the diagnosis of index PE and/or if the patient don't consent to participate to the prospective interventional phase.
For patients died between the inclusion in one of the studies of the INNOVTE network and the time of the selection for the PREVA-CTEPH study, the date and the cause of death are recorded. The same data of the retrospective phase are retrieved.
All cases of CTEPH are adjudicated by an independent committee. In this case, initial Imaging data (CT pulmonary angiography and echocardiography) performed at the time of index PE diagnosis are retrieved for searching previous sign of CTEPH.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dyspnea assessment (NYHA functional class) EKG Echocardiography
Time frame: 30-day +/- 15 days after inclusion visit
Cumulated incidence rate of CTEPH after pulmonary embolism
Time frame: 30-day +/- 15 days after inclusion visit
Cumulated incidence rate of CTEPH in patients without previous signs of CTEPH at the time of index PE diagnosis
Time frame: 30-day +/- 15 days after inclusion visit
Cumulated incidence rate of CTEPH in patients with previous signs of CTEPH at the time of index PE diagnosis
Time frame: 30-day +/- 15 days after inclusion visit
Hazard ratio of risk factors independently and significantly associated with the diagnosis of CTEPH after pulmonary embolism
Time frame: 30-day +/- 15 days after inclusion visit
Complication rate of right heart catheterization
Time frame: 30-day +/- 15 days after inclusion visit
Complication rate of pulmonary angiography
Assistance Publique - Hôpitaux de Paris
Other
Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism. History of the Diagnosis. (Preva-CTEPH) Study
Acronym: Preva-CTEPH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02429284
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
La Jolla, California, United States
View Trial DetailsNCT07172334
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Bordeaux, France
View Trial DetailsNCT07667829
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Beijing, Beijing Municipality, China
View Trial DetailsNCT06015529
Cardiovascular Diseases, Embolism
Brussels, Belgium
View Trial Details